[Clopidogrel and thrombopenia. A case report].
We report our experience with a case of isolated profound thrombocytopenia after clopidogrel (thienopyridine) administration. No adverse event such as bleeding or thrombotic event had occurred, although clopidogrel has been discontinued two weeks after the coronary artery stenting. Despite the safety of clopidogrel, this case demonstrates that clopidogrel can be associated not only with thrombotic thrombocytopenic purpura but also with isolated thrombocytopenia.
Helft
G
G
Service de Réadaptation Cardiovasculaire, Lamotte-Beuvron (41), France. gerard.helft@psl.ap-hop-paris.fr
Elalamy
I
I
Laudy
C
C
Tran
D
D
Beygui
F
F
Le Feuvre
C
C
Ounissi
F
F
Monnet de Lorbeau
B
B
Khellaf
C
C
Metzger
J P
JP
D015906:Angioplasty, Balloon, Coronary; D000077144:Clopidogrel; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010976:Platelet Count; D015607:Stents; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced*; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine